When a shortage of brand-name weight-loss drugs like Ozempic and Wegovy cleared the way for companies like Hims to fill the gap with cheaper, compounded versions, customers came flocking. But in February, the US Food and Drug Administration announced the shortage was over, leaving the company's strategy in flux and some investors worried.

On today’s Big Take podcast, host David Gura and Bloomberg healthcare reporter Madison Muller track how Hims became the king of copycat weight-loss drugs and what’s next for the company as it fights to hold onto the crown.

Read more: How Hims Became the King of Knockoff Weight-Loss Drugs

Cheap Ozempic Knockoffs Are Suddenly Everywhere. Are They Safe?

The Weight-Loss Drug Boom’s Prescription Problem

Listen and follow The Big Take on Apple Podcasts, Spotify or wherever you get your podcasts.

See omnystudio.com/listener for privacy information.

Hims Wants to Keep Mailing You Copycat GLP-1s. It’s Getting Trickier.

Big Take

Hims Wants to Keep Mailing You Copycat GLP-1s. It’s Getting Trickier.